martes, 20 de noviembre de 2018

Draft Recommendation Statement and Draft Evidence Review: Pre-Exposure Prophylaxis for the Prevention of HIV Infection - US Preventive Services Task Force

Opportunity for Public Comment - US Preventive Services Task Force

U.S. Preventive Services Task Force banner



Draft Recommendation Statement and Draft Evidence Review:

Pre-Exposure Prophylaxis for the Prevention of HIV Infection

Public Comment on Draft Recommendation Statement and Draft Evidence Review: Pre-Exposure Prophylaxis for the Prevention of HIV Infection

The U.S. Preventive Services Task Force seeks comments on a draft recommendation statement and draft evidence review on pre-exposure prophylaxis (PrEP) for the prevention of HIV infection. The Task Force found that clinicians should offer PrEP to people at high risk for HIV. The draft recommendation statement and draft evidence review are available for review and public comment from November 20, 2018 to December 26, 2018 here.
The Draft Recommendation Statement and Draft Evidence Review Are Open to Public Comment
review and comment

COMMENTING DETAILS

Public Comment Period:

11/20/18-12/26/18

Any visitor to the Task Force Web site can comment on any of the listed USPSTF draft documents. However, readers should note that the USPSTF writes these documents for researchers, primary care doctors, and other health care providers, using medical and scientific language as appropriate for these audiences.

DRAFT RECOMMENDATION SUMMARY

Population
Recommendation
Grade
Persons at high risk of HIV acquisition
The USPSTF recommends that clinicians offer pre-exposure prophylaxis (PrEP) with effective antiretroviral therapy to persons who are at high risk of HIV acquisition.
A

WHERE WE ARE IN THE PROCESS

Draft Research Plan
Final Research Plan
Draft Recommendation / Draft Evidence Review
Final Recommendation / Evidence Summary

No hay comentarios: